ClinPGx Blog (Page 44)

Sign in Subscribe

More issues

How does methylene blue work in the treatment of methemoglobinemia?

Methylene blue is a drug with many clinical applications, including treatment of infectious diseases such as malaria, a cyanide antidote, a dye for diagnostics, and even has the potential as a therapy for Alzheimer Disease and septic shock. It is indicated for the treatment of drug-induced methemoglobinemia - an increase

SLCO1B1 Haplotypes updated on PharmGKB

The PharmGKB Haplotype table for SLCO1B1 has just been updated and now contains information for alleles *1-*36. The literature includes two different alleles which were both named *16 at the time of publication, and we are using the definition for the first *16 allele to be published. References are

Curators' Favorite Papers

Russ Altman’s recent commentary in Clinical Pharmacology & Therapeutics highlights the importance of integrating personal genomic information with traditional health information in order to use it for 'personalized medicine' [PMID: 23241835]. PharmGKB’s PI uses a hypothetical example to illustrate how general population-based data can be

(Untitled)

We have updated the pathway: Tamoxifen PK pathway. Tamoxifen is a selective estrogen receptor modulator. It is used to treat estrogen receptor positive breast cancer, and has been shown to decrease disease recurrence and mortality rates by 50% and 30%, respectively. PharmGKB's Tamoxifen PK pathway describes the metabolism

Personalized Medicine World Conference 2013

PharmGKB curators attended the PMWC this week, featuring talks covering different areas and aspects of personalized medicine, including pharmacogenetics, co-drug and diagnostics development, adaptation of clinical trials, systems medicine, wellness, sequencing technologies, and implementation.

CPIC guidelines for TPMT and Thiopurine dosing: Update 2013

The 2013 update of the CPIC guidelines for TPMT and Thiopurine dosing is now available online, as an accepted article preview. CPIC genotype-based dosing guidelines are reviewed and updated every two years in order to be clinically current - this is the first update to be released. After an extensive

Additional EMA drug labels released on PharmGKB

Our collection of drug labels containing pgx information from the European Medicines Agency has been extended: Boceprevir and IL28 Brentuximab vedotin and CD30 (TNFRSF8) Capecitabine and DYPD Cetuximab and KRAS Crizotinib and ALK Dasatinib and the Philadelphia chromosome Eltrombopag and F5, SERPINC1 Everolimus and ERBB2 (HER2) Fulvestrant and estrogen receptor

Tailored therapy in asthma? ADRB2 genotype in the context of salmeterol therapy

In a recent trial, asthmatic children homozygous for the beta2-adrenergic receptor Arg16 variant (ADRB2 gene, rs1042713 genotype AA) were randomized and treated with either salmeterol (a beta2-adrenergic receptor agonist) or montelukast (a leukotriene receptor antagonist), both combined with fluticasone. Those in the montelukast treatment group displayed significantly better

CP&T Issue Focuses on Personalized Medicine

The October 2012 issue of Clinical Pharmacology & Therapeutics focuses on individualized medicine including articles that discuss, reveal and tackle key issues in the field of PGx, and provides examples of current clinical implementation projects. Clinical Pharmacology & Therapeutics Volume 92, Issue 4 (October 2012) Amongst these are articles by

CPIC publishes guidelines on interpreting genetic test results for HLA-B*5801 when prescribing allopurinol therapy.

Allopurinol is an analog of the purine base hypoxanthine. It inhibits the conversion of hypoxanthine and xanthine to uric acid by XDH and is used in the treatment of gout. Severe cutaneous adverse reaction, SCAR, also known as allopurinol hypersensitivity syndrome, is a rare serious and sometimes fatal side effect